Lymphoma

Tazemetostat, a first-in-class EZH2 inhibitor, has demonstrated single-agent antitumor activity in patients with relapsed or refractory follicular lymphoma, according to data presented at the 2019 American Society of Hematology (ASH) annual meeting. Results of a phase 2 clinical trial showed an overall response rate of 69% and 35% in mutant and wild-type cohorts, respectively. Clinical activity was durable across both cohorts, with patients on therapy up to 2 years and responses continuing to deepen over time, researchers in the study reported. Read More ›

Nivolumab monotherapy can be used as an effective bridge therapy to autologous hematopoietic cell transplantation (AHCT) in many patients with relapsed or refractory Hodgkin lymphoma (HL), researchers reported at ASH 2019. Read More ›

  • Calquence Receives FDA Approval for the Treatment of Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
  • Despite Some Positive Trends, Report Confirms Lung Cancer Remains the Deadliest Form of Cancer
Read More ›

  • Teva Will Resume Production of Vincristine in Response to Shortage
  • FDA Fast-Tracks Opdivo plus Yervoy Regimen for Treatment of Advanced Liver Cancer
  • FDA Grants Accelerated Approval to Brukinsa for Patients with Mantle-Cell Lymphoma
Read More ›

On January 14, 2019, the FDA approved cabozantinib (Cabometyx; Exelixis) an oral multitargeted tyrosine kinase inhibitor, for the treatment of patients with hepatocellular carcinoma who were previously treated with sorafenib (Nexavar). Read More ›

Zanubrutinib, a highly specific and irreversible next-generation Bruton’s tyrosine kinase (BTK) inhibitor, exhibited excellent activity in a single-arm, open-label multicenter phase 2 clinical trial of patients with relapsed or refractory mantle-cell lymphoma (MCL). Early study results were reported at ASH 2018. Read More ›





Subscribe to
Oncology Practice Management

Stay up to date with oncology news & updates by subscribing to recieve the free OPM print publications or weekly e‑Newsletter.

I'd like to recieve: